Lixte Biotechnology Holdings Inc (LIXT)
2.882
0.00 (0.00%)
USD |
NASDAQ |
May 02, 16:00
2.99
+0.11
(+3.74%)
Pre-Market: 09:08
Lixte Biotechnology Holdings Enterprise Value: 5.779M for May 2, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 02, 2024 | 5.779M |
| May 01, 2024 | 5.774M |
| April 30, 2024 | 5.505M |
| April 29, 2024 | 6.359M |
| April 26, 2024 | 6.629M |
| April 25, 2024 | 6.539M |
| April 24, 2024 | 6.674M |
| April 23, 2024 | 6.539M |
| April 22, 2024 | 6.832M |
| April 19, 2024 | 7.090M |
| April 18, 2024 | 6.834M |
| April 17, 2024 | 6.787M |
| April 16, 2024 | 7.169M |
| April 15, 2024 | 6.719M |
| April 12, 2024 | 7.124M |
| April 11, 2024 | 6.899M |
| April 10, 2024 | 6.854M |
| April 09, 2024 | 6.742M |
| April 08, 2024 | 6.742M |
| April 05, 2024 | 6.494M |
| April 04, 2024 | 6.989M |
| April 03, 2024 | 6.269M |
| April 02, 2024 | 7.619M |
| April 01, 2024 | 7.326M |
| March 28, 2024 | 6.899M |
| Date | Value |
|---|---|
| March 27, 2024 | 7.214M |
| March 26, 2024 | 4.369M |
| March 25, 2024 | 4.369M |
| March 22, 2024 | 4.246M |
| March 21, 2024 | 4.491M |
| March 20, 2024 | 4.492M |
| March 19, 2024 | 4.470M |
| March 18, 2024 | 4.807M |
| March 15, 2024 | 4.492M |
| March 14, 2024 | 4.402M |
| March 13, 2024 | 4.650M |
| March 12, 2024 | 4.605M |
| March 11, 2024 | 4.937M |
| March 08, 2024 | 4.762M |
| March 07, 2024 | 5.010M |
| March 06, 2024 | 4.740M |
| March 05, 2024 | 4.819M |
| March 04, 2024 | 4.852M |
| March 01, 2024 | 4.744M |
| February 29, 2024 | 5.145M |
| February 28, 2024 | 5.358M |
| February 27, 2024 | 5.302M |
| February 26, 2024 | 4.268M |
| February 23, 2024 | 4.29M |
| February 22, 2024 | 4.620M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
2.713M
Minimum
Dec 11 2023
91.03M
Maximum
Sep 30 2019
33.39M
Average
25.17M
Median
Oct 27 2021
Enterprise Value Benchmarks
| iBio Inc | 16.94M |
| PAVmed Inc | 77.91M |
| PDS Biotechnology Corp | 103.56M |
| Moleculin Biotech Inc | -12.08M |
| Syros Pharmaceuticals Inc | 39.52M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.032M |
| Total Expenses (Quarterly) | 1.026M |
| EPS Diluted (Quarterly) | -0.41 |
| Earnings Yield | -93.68% |